SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
Rhea-AI Summary
SciSparc (Nasdaq: SPRC) reported that majority-owned subsidiary NeuroThera Labs (TSXV: NTLX) completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million. SciSparc invested C$2.7 million, subscribing for 22,500,000 units at C$0.12 per unit, representing 50% of the financing.
Each unit includes one NeuroThera common share and one three-year warrant, with an acceleration feature tied to a potential Nasdaq listing. Following the financing, SciSparc holds approximately 44.6% of NeuroThera’s common shares, and its stake is valued at about C$30 million. NeuroThera plans to use the net proceeds for general working capital and corporate and administrative expenses.
Positive
- C$5.4 million total gross proceeds raised by NeuroThera Labs
- SciSparc invested C$2.7 million, representing 50% of the financing
- SciSparc now holds approximately 44.6% of NeuroThera’s common shares
- SciSparc’s stake in NeuroThera valued at approximately C$30 million
- Subscription for 22,500,000 units including three-year share purchase warrants
Negative
- SciSparc deployed C$2.7 million of its cash into NeuroThera’s financing
Market reaction after private placement financing: SPRC +5.27%
Following this news, SPRC has gained 5.27%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.8% during the session. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $6.99. Trading volume is exceptionally heavy at 21.0x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | Japanese patent grant | Positive | -3.2% | Japanese patent grant for NeuroThera’s proprietary therapeutic combination |
| Aug 05 | Phase IIb trial launch | Positive | +2.2% | Phase IIb Tourette Syndrome trial launched at Yale Child Study Center |
| Jul 31 | Quantum workflow demonstration | Positive | -18.2% | End-to-end hybrid quantum-classical workflow demonstrated for clinical data analytics |
| Jul 29 | Quantum workflow validation | Positive | +70.5% | Internal validation completed for quantum sampling clinical-data workflow |
| Jul 27 | Agentic AI strategy | Neutral | -6.0% | Board approved targeting agentic artificial intelligence market |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history showed mixed reactions: two positive announcements aligned with gains, while three announcements were followed by declines.
Key Terms
non-brokered private placements financial
acceleration provision financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SciSparc Invests C
TEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its majority-owned subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C
SciSparc participated in the financing with a C
Following the financing, SciSparc will hold approximately
NeuroThera intends to use the net proceeds from the financing for general working capital purposes and other corporate and administrative expenses.
About SciSparc Ltd. (Nasdaq: SPRC):
The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
About NeuroThera Labs Inc.
NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the intended use of proceeds by NeuroThera from its financing. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
